Tenderwize
Back to tender search

Non-exclusive drug discount agreement for Interferon beta-1b via Open-House model

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline May 31, 2028 · 600 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Interferon beta-1b (ATC-Code nach WHO: L03AB08)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

40 / 100

Complexity

30 / 100

Risk factors

No minimum volume commitments; actual demand depends on prescribing patterns and patient numbers.

The buyer may terminate the open-house procedure early if exclusive agreements are signed, ending all non-exclusive agr...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
May 31, 2028

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Non-exclusive framework agreement for the supply of Interferon beta-1b (ATC L03AB08) to AOK PLUS insured members in Saxony and Thuringia.
  • Agreement under §130a(8) SGB V for drug discount contracts.
Show full summary

Open-house procedure for non-exclusive pharmaceutical discount agreements for Interferon beta-1b (ATC L03AB08), organized by AOK PLUS for Saxony and Thuringia. The procedure is not a public procurement under EU directives but a voluntary transparency initiative. The framework agreement has no guaranteed volumes, no exclusivity, and runs until 31 May 2028. Submissions are accepted periodically according to a schedule provided in the project room.

Risks

No minimum volume commitments; actual demand depends on prescribing patterns and patient numbers.

The buyer may terminate the open-house procedure early if exclusive agreements are signed, ending all non-exclusive agr...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4(18) AMG with respect to the offered drugs.
  • Must have registered office in Germany, EU, or EEA (per §9(2) AMG).

Eligibility

  • Submit completed declarations: self-declaration on exclusion grounds and Russia sanctions declaration.

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria; the procedure is open-house with no competitive evaluation.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive drug discount agreement for Interferon beta-1b via Open-House model

Non-exclusive framework agreement for the supply of Interferon beta-1b under §130a(8) SGB V. No minimum volume commitment. Multiple pharmaceutical entrepreneurs may participate simultaneously. The contract ends 31 May 2028.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

May 2026 - May 2028

Category

Pharmaceutical products

Award Criteria

No award criteria; the procedure is open-house with no competitive evaluation.

Procurement Details

Publication date
12 Mar 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
176917-2026

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30